Enanta Pharmaceuticals stock
ENTANASDAQEnanta Pharmaceuticals, Inc., HealthcareISIN US29251M1062
28Score 28 out of 100, Weak
Price and trend
46 / 100
Price history
−6.1% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 34% below its 52-week high. Largest decline in 14 years: 97% (July 2018 to April 2025).
Chart figures for advanced users
- SMA 50$12.01
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.11
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.08
- The lowest closing price of the last twelve months.
- Resistance$16.85
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Enanta Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $326.2M, is number 283 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $65.32M (down 3.4% year on year) and a loss of $81.89M.
- For fiscal 2026, analysts expect on average revenue of $64.75M (down 0.9%) and adjusted earnings per share of −$2.29.
Show more
- MEQIRI Score 28 out of 100 (Weak): rank 704 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- High debtDebt 3.11 times equity (fiscal 2025), Biotechnology median 0.09.Stability 28
- Loss-makingLoss of $63.23M over the last 12 months.Fundamentals 20
- Revenue shrinkingRevenue down 11.8% a year since 2020.Growth 21
The score is held back by fundamentals and capital allocation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 26 to 28.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 0.7% on the twelve months before. Revenue has grown solidly since 2010, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating −131%, net −125%. Last 12 months: net −97%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 16 Nov 2026in 4 days
- Last reported
- 10 Aug 2026EPS reported −$0.67 (expected −$0.51)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.200.0%
- Revenue
- $60.42M0.0%
- Earnings per share
- −$2.670.0%
- Revenue
- $58.85M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Capps Kathleen S.Sale
5 Dec 2025, See Remarks
- Shares
- 323
- Price
- $14.23
- Value
- $4,596
- Trout Harry R. IIISale
5 Dec 2025, See Remarks
- Shares
- 542
- Price
- $14.23
- Value
- $7,713
- Rottinghaus Scott T.Sale
5 Dec 2025, Chief Medical Officer
- Shares
- 798
- Price
- $14.23
- Value
- $11,356
Show 5 more
- Luu BrendanSale
5 Dec 2025, Chief Business Officer
- Shares
- 1,394
- Price
- $14.23
- Value
- $19,837
- Kieffer Tara LynnSale
5 Dec 2025, Chief Product Strategy Officer
- Shares
- 2,106
- Price
- $14.23
- Value
- $29,968
- Or Yat SunSale
5 Dec 2025, Chief Scientific Officer
- Shares
- 2,390
- Price
- $14.23
- Value
- $34,010
- Luly Jay R.Sale
5 Dec 2025, President and CEO
- Shares
- 4,743
- Price
- $14.23
- Value
- $67,493
- Capps Kathleen S.Sale
2 Dec 2025, See Remarks
- Shares
- 207
- Price
- $13.96
- Value
- $2,890
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Enanta Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 28
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Century TherapeuticsIPSC $358.05M37
- AgomAb TherapeuticsAGMB $344.24M30
- Faeth TherapeuticsFTH $344.15M35
- Atea PharmaceuticalsAVIR $338.46M35
- Autolus TherapeuticsAUTL $330.04M31
- OcugenOCGN $325.87M36
- Turn TherapeuticsTTRX $320.99M45
- MapLight TherapeuticsMPLT $318.78M33
ETFs that hold Enanta Pharmaceuticals
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.